🟢 Abbott is trading 10.9% up today after Q2 earnings beat and raised full-year guidance

Abbott is trading 10.9% up now at $99.04 after reporting stronger-than-expected second-quarter 2026 results and raising its full-year outlook.

• The company reported sales of $12.59 billion and adjusted EPS of $1.31, surpassing analyst estimates behind strong growth in Medical Devices and Diagnostics.
• Management raised its 2026 adjusted EPS guidance to a range of $5.45–$5.60, citing the rapid integration of the Exact Sciences acquisition.